D.E. Shaw & Co
PEAR

D.E. Shaw & Co’s Pear Therapeutics, Inc. Class A Common Stock PEAR Stock Holding History

D.E. Shaw & Co’s Portfolio PEAR Stock Details PEAR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-39,244
Closed -$198K – 5963
2022
Q1 		$198K Buy
+39,244
New +$178K ﹤0.01% 4873
2021
Q4 		– Sell
-277,432
Closed -$2.76M – 5829
2021
Q3 		$2.76M Hold
277,432
– – ﹤0.01% 2709
2021
Q2 		$2.74M Buy
+277,432
New +$2.72M ﹤0.01% 2616

Other funds holding PEAR

Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
SGA
SB Global Advisers London, United Kingdom $861M AUM 71.72% 1-Year Est. Return
AV
Arboretum Ventures Ann Arbor, Michigan $1.72M AUM 82.7% 1-Year Est. Return
TAA
TB Alternative Assets Grand Cayman, Cayman Islands $623M AUM 154.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PT
Palantir Technologies Denver, Colorado $9.72M AUM 6.46% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

D.E. Shaw & Co's PEAR Position: Q2 2022 in Review

D.E. Shaw & Co sold out of Pear Therapeutics, Inc. Class A Common Stock (PEAR) in Q2 2022, closing a stake of 39,244 shares — an estimated $198K sold.

D.E. Shaw & Co first reported a position in PEAR in Q2 2021 and held it in 3 quarters. The position peaked at $2.76M in Q3 2021. 40 funds tracked by Wall St. Rank hold PEAR as of Q2 2022.

  • D.E. Shaw & Co reported no remaining Pear Therapeutics, Inc. Class A Common Stock position as of Q2 2022 after selling out during the quarter.
  • D.E. Shaw & Co sold 39,244 Pear Therapeutics, Inc. Class A Common Stock shares in Q2 2022, an estimated $198K.
  • D.E. Shaw & Co first reported a position in Pear Therapeutics, Inc. Class A Common Stock in Q2 2021 and held it in 3 quarters.
  • D.E. Shaw & Co's Pear Therapeutics, Inc. Class A Common Stock position peaked at $2.76M in Q3 2021.
  • 40 funds tracked by Wall St. Rank held Pear Therapeutics, Inc. Class A Common Stock as of Q2 2022.

Based on D.E. Shaw & Co's 13F filing for Q2 2022, filed 15 Aug 2022.